Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

The role of LIM domain-containing protein 1 (LIMD1) in the multidrug resistance of colorectal carcinoma (CRC) has not yet been established. The aim of the current study was to investigate the chemosensitivity of CRC multidrug-resistant (MDR) cells following the silencing of LIMD1. The MDR phenotypic Colo205 and HCT-8 cell lines were examined, which were established by exposure to increasing doses of 5-fluorouracil (5-FU) over a period of one year. LIMD1 siRNA constructs were transfected into CRC MDR cells and the phenotypic effects were determined comprehensively. The Colo205 and HCT-8 cell lines were more resistant to 5-FU compared with their respective parental cell lines. In addition, the two MDR cell types expressed significantly more LIMD1 compared with their parental lines. The stably transfected cells showed various degrees of reversal of the MDR phenotype, and 5-FU-induced apoptosis was increased in the transfected cells compared with the controls. In conclusion, RNA interference targeting LIMD1 may present a novel therapeutic option for CRC.

Cite

CITATION STYLE

APA

Chen, Z., Zhu, X., Xie, T., Xie, J., Quo, K., & Liu, X. (2014). Drug resistance reversed by silencing LIM domain-containing protein 1 expression in colorectal carcinoma. Oncology Letters, 8(2), 795–798. https://doi.org/10.3892/ol.2014.2155

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free